
Releases
Servier showcases new pediatric glioma data at ISPNO 2026
At the International Symposium on Pediatric Neuro-Oncology in Sydney, Servier is presenting three-year follow-up data from the FIREFLY-1 study, highlighting the efficacy of tovorafenib in treating BRAF-altered pediatric low-grade glioma while addressing the critical role of caregiver-physician communication in long-term treatment outcomes.

























